$4.12
-0.16 (-3.74%)
Open$4.35
Previous Close$4.28
Day High$4.36
Day Low$4.00
52W High$11.47
52W Low$1.35
Volume—
Avg Volume571.8K
Market Cap295.22M
P/E Ratio—
EPS$-10.50
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+589.8% upside
Current
$4.12
$4.12
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 36.69M | 38.69M | 57.05M |
| Net Income | -537,342,141 | -510,081,137 | 9.29M |
| Profit Margin | -1,464.6% | -1,391.4% | 16.3% |
| EBITDA | -478,442,026 | -479,400,827 | 17.50M |
| Free Cash Flow | — | — | 7.43M |
| Rev Growth | -5.2% | -5.2% | +3.4% |
| Debt/Equity | 3.41 | 3.41 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |